The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
Nineteen people have been rescued from the English Channel after the inflatable boat they were in started taking on water.
Leishang Cosmetics said it strongly condemns racial discrimination but blamed foreign media for the "over-amplification" of the advert.
The public voted the ITV show ahead of last year's winner EastEnders, as well as Coronation Street, Doctors and Hollyoaks.